Polygenic burden analysis of longitudinal clusters of ... · Polygenic burden analysis of...

1
Polygenic burden analysis of longitudinal clusters of quality of life and functioning in patients with severe mental illness Fanny Aldinger 1 *, Ashley Comes 1,2 *, Ivan Kondofersky 3,4 , Krisna Adorjan 1 , Heike Anderson-Schmidt 1 , Till F.M. Andlauer 5 , Monika Budde 1 , Katrin Gade 1 , Urs Heilbronner 1 , Janos Kalman 1 , Sergi Papiol 1 , Fabian J. Theis 3,4 , Peter Falkai 6 , Nikola S. Müller 4 & Thomas G. Schulze 1 1 Instute of Psychiatric Phenomics and Genomics, Medical Center of the University of Munich, Munich, Germany 2 Internaonal Max Planck Research School for Translaonal Psychiatry (IMPRS-TP), Kraepelinstr. 2-10, 80804 Munich, Germany 3 Center for Mathemacs, Chair of Mathemacal Modeling of Biological Systems, Technical University Munich, Garching, Germany 4 Instute of Computaonal Biology, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany 5 Department of Translaonal Research in Psychiatry, Max Planck Instute of Psychiatry, Munich, Germany 6 Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Munich, Germany * These authors contributed equally Background Psychiatric illnesses such as bipolar disorder (BD), schizophrenia (SZ) and schizoaffecve disorder (SZA) are severe, disabling disorders associated with decreased quality of life (QOL) and funco- ning (1–3). Sgmazaon, co-morbidies, adverse effects of medicaons, care models with de- ficits in personal and social recovery needs and chronic symptoms due to treatment resistance are factors that can lead to severe reducons in quality of life and funconing (4,5). In this study we aim to characterize paents with good and poor outcomes according to QOL and funconing scores across diagnoses. Using cluster analysis, we sought to idenfy longitudinal trajectories and invesgate whether levels of QOL and funconing are associated with the individual burden of schizophrenia polygenic risk scores (SZ-PRS). Determining clusters of paents at higher risk of poorer outcomes is crical to provide early and effecve intervenons. Methods Participants Longitudinal data was used from the Clinical Research Group 241 and PsyCourse studies in Germany and Austria (www.kfo241.de; www.PsyCourse.de). Parcipants were phenotyped using a comprehensive baery which included data on socio-demographics, history of illness, symptomatology, QOL and funconing. Data was collected at four equidistant me points over an 18-month period. The selected sample comprised a total of 198 parcipants (age 46.9 +- 12.4 years; 46% females) with a DSM-IV diagnosis of SZ, SZA or BD and completed study period. Genotyping and polygenic scoring The Infinium Psycharray from Illumina was used to genotype paents. For imputaon the 1000 Genomes Phase 3 reference panel was used. SZ-PRS were calculated for all individuals using PLINK 1.07. Allelic effect sizes and P-values were determined ulizing the PGC2 SZ results as a discovery sample. Statistical analyses 1) A set of 111 longitudinally measured variables on QOL (WHOQOL-BREF), funconing scores (GAF) and the current work status were selected for cluster analyses. 2) Factor analysis for mixed data (FAMD) (6) was applied to reduce the dimensionality and idenfy key structures of the data. This allowed for the computaon of abstract data dimensions which were used for calculaon of longitudinal trajectories. 3) These trajectories can be seen as a representaon of the overall status of paents and both the overall level as well as the longitudinal change of this status were used as inputs for a k-mean clustering for longitudinal data (7). This, in turn, resulted in the idenficaon of three disnct subpopulaons of paents. 4) In a linear regression model we used clusters as predicve variables for polygenic risk scores at 11 thresholds. Results The dimension which explained the most variance was used for cluster analysis. Com- puted by FAMD, the strongest loadings on the first dimension were observed for self-sa- sfacon, life enjoyment, and ability to cope with daily tasks, energy, and quality of life. Three clusters of longitudinal trajectories were observed on the first dimension: clus- ter A (39.4%) consisted of parcipants with the highest average scores for funconing and QOL, cluster B (33.8%) including parcipants with the lowest average scores for funco- ning and QOL, and cluster C (26.8%) consisng of parcipants who had great improvement in funconing and QOL scores over the course of the longitudinal study (see Figure 2). References 1. Bobes J, Garcia-Porlla MP, Bascaran MT, Saiz PA, Bousoño M. Quality of life in schizophrenic paents. Dialo- gues Clin Neurosci. 2007;9(2):215–26. 2. Merikangas KR, Jin R, He J, Kessler RC, Lee S, Sampson NA, et al. NIH Public Access. 2012;68(3):241–51. 3. Latalova K, Prasko J, Diveky T, Kamaradova D, Velartova H. Cognive dysfuncon, dissociaon and quality of life in bipolar affecve disorders in remission. Psychiatr Danub. 2010;22(4):528–34. 4. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Prim. 2015;1:15067. 5. Sum MY, Ho NF, Sim K. Cross diagnosc comparisons of quality of life deficits in remied and unremied pa- ents with schizophrenia and bipolar disorder. Schizophr Res. 2015;168(1-2):191–6. 6. Pagès J. Analyse factorielle de données mixtes. Rev Stat Appliquée. Société française de stasque; 52(4):93– 111. 7. Genolini C, Pingault JB, Driss T, Côté S, Tremblay RE, Vitaro F, et al. KmL3D: a non-parametric algorithm for clustering joint trajectories. Comput Methods Programs Biomed. 2013;109(1):104–11. Acknowledgements We thank all of the paents for parcipang in this study. This research was funded by the Deut - sche Forschungsgemeinschaſt (DFG). Schulze: DFG SCHU 1603/5-1, SCHU 1603/7-1; Theis: DFG TH 900/9-1 Disclosure The authors declare no conflict of interest. Conclusion The results are preliminary and have to be interpreted with cauon. Nevertheless, the approach of longitudinal clustering to idenfy cross-diagnosc subgroups based on a common phenoty - pe seems to be promising. Phenotypic data provide insight to target sufferers of severe mental illness with worse outcomes. Levels of funconing and QOL seem to be associated with SZ-PRS. These analyses will be replicated using the next wave dataset. We expect our findings to remain constant with increased power to reach significance. We hope to explore these clusters further through invesgaon of proteomics and epigenecs in the near future. 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5 0 5 10 Times V1 A A B C A B C : 39.4% : 33.8% : 26.8% 1.0 1.5 2.0 2.5 3.0 3.5 4.0 5 0 5 10 time Dim 1 There was no significant asso- ciaon between cluster mem- bership and SZ-PRS in the single models. Non-significant trends: Cluster B members show higher polygenic burden versus Clus- ter A. Cluster C members have less polygenic burden than Clus- ter A. Overall, SZ-PRS at certain thresholds can be predicted by the clusters (see Figure 4). INTERNATIONAL MAX PLANCK RESEARCH SCHOOL FOR TRANSLATIONAL PSYCHIATRY Figure 1 Recruing centers in Germany and Austria Figure 2 Individual trajectories: values on dimension 1 at four me points. Figure 3 Cluster A, B, C: values on dimension 1 at four me points Table 1 Descripve data of clusters A, B, C Figure 4 SZ-PRS Explained variance for polygenic risk scores at various thresholds Cluster A Cluster B Cluster C % % % SZ n= 98 47.5 55.2 45.3 BD I/II n= 76 39.7 31.3 45.3 SZA n= 24 12.8 13.4 9.4 Sex females 41.0 35.7 43.3 Unemployed 41.0 62.7 47.2 Part-time 24.4 26.9 22.6 Full-time 34.6 10.4 30.2 Inpatient 85.1 74.6 71.7 Day unit 1.4 6.0 3.8 Outpatient 13.5 19.4 24.5 mean, SD mean, SD mean, SD Age at interview 47.8, 13.4 46.4, 10.8 46.9, 12.9 Age at onset 31.0, 12.3 28.6, 10.5 29.1, 9.8 Duration of illness 16.4, 12.2 17.8, 10.9 17.8, 11.8 GAF average 66.3, 10.4 53.3, 9.3 64.4, 9.5 GAF gain 3.4, 12.1 2.0, 12.3 9.9, 10.1

Transcript of Polygenic burden analysis of longitudinal clusters of ... · Polygenic burden analysis of...

  • Polygenic burden analysis of longitudinal clusters of quality of life and functioning

    in patients with severe mental illnessFanny Aldinger1*, Ashley Comes1,2*, Ivan Kondofersky3,4, Kristina Adorjan1, Heike Anderson-Schmidt1, Till F.M. Andlauer5,

    Monika Budde1, Katrin Gade1, Urs Heilbronner1, Janos Kalman1, Sergi Papiol1, Fabian J. Theis3,4, Peter Falkai6, Nikola S. Müller4 & Thomas G. Schulze1

    1 Institute of Psychiatric Phenomics and Genomics, Medical Center of the University of Munich, Munich, Germany2International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Kraepelinstr. 2-10, 80804 Munich, Germany

    3 Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technical University Munich, Garching, Germany4Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Munich, Germany

    5 Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany 6 Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Munich, Germany

    * These authors contributed equally

    BackgroundPsychiatric illnesses such as bipolar disorder (BD), schizophrenia (SZ) and schizoaffective disorder (SZA) are severe, disabling disorders associated with decreased quality of life (QOL) and functio-ning (1–3). Stigmatization, co-morbidities, adverse effects of medications, care models with de-ficits in personal and social recovery needs and chronic symptoms due to treatment resistance are factors that can lead to severe reductions in quality of life and functioning (4,5). In this study we aim to characterize patients with good and poor outcomes according to QOL and functioning scores across diagnoses. Using cluster analysis, we sought to identify longitudinal trajectories and investigate whether levels of QOL and functioning are associated with the individual burden of schizophrenia polygenic risk scores (SZ-PRS). Determining clusters of patients at higher risk of poorer outcomes is critical to provide early and effective interventions.

    MethodsParticipants Longitudinal data was used from the Clinical

    Research Group 241 and PsyCourse studies in Germany and Austria (www.kfo241.de; www.PsyCourse.de). Participants were phenotyped using a comprehensive battery which included data on socio-demographics, history of illness, symptomatology, QOL and functioning. Data was collected at four equidistant time points over an 18-month period. The selected sample comprised a total of 198 participants (age 46.9 +- 12.4 years; 46% females) with a DSM-IV diagnosis of SZ, SZA or BD and completed study period.

    Genotyping and polygenic scoring The Infinium Psycharray from Illumina was used to genotype patients. For imputation the 1000 Genomes Phase 3 reference panel was used. SZ-PRS were calculated for all individuals using PLINK 1.07. Allelic effect sizes and P-values were determined utilizing the PGC2 SZ results as a discovery sample.

    Statistical analyses 1) A set of 111 longitudinally measured variables on QOL (WHOQOL-BREF), functioning scores (GAF) and the current work status were selected for cluster analyses. 2) Factor analysis for mixed data (FAMD) (6) was applied to reduce the dimensionality and identify key structures of the data. This allowed for the

    computation of abstract data dimensions which were used for calculation of longitudinal trajectories.

    3) These trajectories can be seen as a representation of the overall status of patients and both the overall level as well as the longitudinal change of this status were used as inputs for a k-mean clustering for longitudinal data (7). This, in turn, resulted in the identification of three distinct subpopulations of patients.

    4) In a linear regression model we used clusters as predictive variables for polygenic risk scores at 11 thresholds.

    ResultsThe dimension which explained the most variance was used for cluster analysis. Com-puted by FAMD, the strongest loadings on the first dimension were observed for self-sa-tisfaction, life enjoyment, and ability to cope with daily tasks, energy, and quality of life.Three clusters of longitudinal trajectories were observed on the first dimension: clus-ter A (39.4%) consisted of participants with the highest average scores for functioning and QOL, cluster B (33.8%) including participants with the lowest average scores for functio-ning and QOL, and cluster C (26.8%) consisting of participants who had great improvement in functioning and QOL scores over the course of the longitudinal study (see Figure 2).

    References1. Bobes J, Garcia-Portilla MP, Bascaran MT, Saiz PA, Bousoño M. Quality of life in schizophrenic patients. Dialo-

    gues Clin Neurosci. 2007;9(2):215–26. 2. Merikangas KR, Jin R, He J, Kessler RC, Lee S, Sampson NA, et al. NIH Public Access. 2012;68(3):241–51. 3. Latalova K, Prasko J, Diveky T, Kamaradova D, Velartova H. Cognitive dysfunction, dissociation and quality of

    life in bipolar affective disorders in remission. Psychiatr Danub. 2010;22(4):528–34. 4. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat

    Rev Dis Prim. 2015;1:15067. 5. Sum MY, Ho NF, Sim K. Cross diagnostic comparisons of quality of life deficits in remitted and unremitted pa-

    tients with schizophrenia and bipolar disorder. Schizophr Res. 2015;168(1-2):191–6. 6. Pagès J. Analyse factorielle de données mixtes. Rev Stat Appliquée. Société française de statistique; 52(4):93–

    111. 7. Genolini C, Pingault JB, Driss T, Côté S, Tremblay RE, Vitaro F, et al. KmL3D: a non-parametric algorithm for

    clustering joint trajectories. Comput Methods Programs Biomed. 2013;109(1):104–11.

    AcknowledgementsWe thank all of the patients for participating in this study. This research was funded by the Deut-sche Forschungsgemeinschaft (DFG). Schulze: DFG SCHU 1603/5-1, SCHU 1603/7-1; Theis: DFG TH 900/9-1

    DisclosureThe authors declare no conflict of interest.

    ConclusionThe results are preliminary and have to be interpreted with caution. Nevertheless, the approach of longitudinal clustering to identify cross-diagnostic subgroups based on a common phenoty-pe seems to be promising. Phenotypic data provide insight to target sufferers of severe mental illness with worse outcomes. Levels of functioning and QOL seem to be associated with SZ-PRS. These analyses will be replicated using the next wave dataset. We expect our findings to remain constant with increased power to reach significance. We hope to explore these clusters further through investigation of proteomics and epigenetics in the near future.

    1.0 1.5 2.0 2.5 3.0 3.5 4.0

    −50

    510

    Times

    V1

    ● ●

    ●A A

    B

    C

    1.0 1.5 2.0 2.5 3.0 3.5 4.0

    −50

    510

    TimesV2

    ● ●●

    ●A AB

    C

    A B C: 39.4% : 33.8% : 26.8%

    2222222222222222

    2222

    5 15

    5060

    7080

    Calinski.HarabatzSorted

    Rerolling

    33333333333333

    3333

    33

    4444444444444444

    4444

    555555555555

    5555555

    5

    1.0 1.5 2.0 2.5 3.0 3.5 4.0

    −50

    510

    time

    Dim

    1

    There was no significant asso-ciation between cluster mem-bership and SZ-PRS in the single models. Non-significant trends: Cluster B members show higher polygenic burden versus Clus-ter A. Cluster C members have less polygenic burden than Clus-ter A. Overall, SZ-PRS at certain thresholds can be predicted by the clusters (see Figure 4).

    INTERNATIONAL MAX PLANCK RESEARCH SCHOOLFOR TRANSLATIONAL PSYCHIATRY

    Figure 1 Recruiting centers in Germany and Austria

    Figure 2 Individual trajectories: values on dimension 1 at four time points.

    Figure 3Cluster A, B, C: values on dimension 1 at four time points

    Table 1 Descriptive data of clusters A, B, C

    Figure 4 SZ-PRS Explained variance for polygenic risk scores at various thresholds

    Cluster A Cluster B Cluster C

    % % %

    SZ n= 98 47.5 55.2 45.3BD I/II n= 76 39.7 31.3 45.3SZA n= 24 12.8 13.4 9.4Sex females 41.0 35.7 43.3Unemployed 41.0 62.7 47.2Part-time 24.4 26.9 22.6Full-time 34.6 10.4 30.2Inpatient 85.1 74.6 71.7Day unit 1.4 6.0 3.8Outpatient 13.5 19.4 24.5

    mean, SD mean, SD mean, SDAge at interview 47.8, 13.4 46.4, 10.8 46.9, 12.9Age at onset 31.0, 12.3 28.6, 10.5 29.1, 9.8Duration of illness 16.4, 12.2 17.8, 10.9 17.8, 11.8GAF average 66.3, 10.4 53.3, 9.3 64.4, 9.5GAF gain 3.4, 12.1 2.0, 12.3 9.9, 10.1